{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T16:23:10Z","timestamp":1789316590214,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["23bk0104126h0003"],"award-info":[{"award-number":["23bk0104126h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.parkreldis.2025.107833","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T22:24:48Z","timestamp":1745101488000},"page":"107833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Allogenic transplantation therapy of iPS cell-derived dopamine progenitors for Parkinson's disease \u2013Current status of the Kyoto Trial and future perspectives\u2013"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-9640","authenticated-orcid":false,"given":"Ryosuke","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hodaka","family":"Yamakado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukatsu","family":"Sawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2025.107833_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.reth.2020.06.002","article-title":"iPS cell-based therapy for Parkinson's disease: a Kyoto trial","volume":"13","author":"Takahashi","year":"2020","journal-title":"Regen Ther"},{"key":"10.1016\/j.parkreldis.2025.107833_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-08700-0","article-title":"Phase I\/II trial of iPSC-derived dopaminergic cells for Parkinson\u2019s disease","author":"Sawamoto","year":"2025","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.parkreldis.2025.107833_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ejn.14109","article-title":"Cell-based therapy for Parkinson's disease: a journey through decades toward the light side of the Force","volume":"49","author":"Parmar","year":"2019","journal-title":"Eur. J. Neurosci."},{"issue":"7","key":"10.1016\/j.parkreldis.2025.107833_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41591-019-0507-2","article-title":"Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease","volume":"25","author":"Barker","year":"2019","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.parkreldis.2025.107833_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202400118","article-title":"The history and status of dopamine cell therapies for Parkinson's disease","volume":"46","author":"Barker","year":"2024","journal-title":"Bioessays"},{"issue":"9","key":"10.1016\/j.parkreldis.2025.107833_bib6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/stmcls\/sxae042","article-title":"Advancing Parkinson's disease treatment: cell replacement therapy with neurons derived from pluripotent stem cells","volume":"42","author":"Clark","year":"2024","journal-title":"Stem Cell."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.107833_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.stemcr.2013.08.007","article-title":"Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate","volume":"1","author":"Morizane","year":"2013","journal-title":"Stem Cell Rep."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107833_bib8","first-page":"51","article-title":"A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population","volume":"4","author":"Yoshida","year":"2023","journal-title":"M\u00e9d. Sur"},{"issue":"6","key":"10.1016\/j.parkreldis.2025.107833_bib9","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1634\/stemcells.2005-0393","article-title":"Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation","volume":"24","author":"Brederlau","year":"2006","journal-title":"Stem Cell."},{"issue":"5","key":"10.1016\/j.parkreldis.2025.107833_bib10","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/stem.1060","article-title":"Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease","volume":"30","author":"Doi","year":"2012","journal-title":"Stem Cell."},{"issue":"10","key":"10.1016\/j.parkreldis.2025.107833_bib11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","article-title":"Transplantation of embryonic dopamine neurons for severe Parkinson's disease","volume":"344","author":"Freed","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.107833_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","article-title":"A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease","volume":"54","author":"Olanow","year":"2003","journal-title":"Ann. Neurol."},{"issue":"38","key":"10.1016\/j.parkreldis.2025.107833_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000976","article-title":"Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants","volume":"2","author":"Politis","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.107833_bib14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.stemcr.2014.01.013","article-title":"Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation","volume":"2","author":"Doi","year":"2014","journal-title":"Stem Cell Rep."},{"issue":"7669","key":"10.1016\/j.parkreldis.2025.107833_bib15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nature23664","article-title":"Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model","volume":"548","author":"Kikuchi","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.parkreldis.2025.107833_bib16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.stem.2017.09.014","article-title":"Human trials of stem cell-derived dopamine neurons for Parkinson's disease: dawn of a new era","volume":"21","author":"Barker","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.parkreldis.2025.107833_bib17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.stem.2024.01.006","article-title":"Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson's disease","volume":"31","author":"Park","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.parkreldis.2025.107833_bib18","series-title":"Safety and Tolerability of Bemdaneprocel in People with Parkinson's Disease: Results up to 24 Months from a Phase 1 Study International Congress of Parkinson's Disease and Movement Disorders","author":"Sarva","year":"2024"},{"issue":"20","key":"10.1016\/j.parkreldis.2025.107833_bib19","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","article-title":"Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease","volume":"382","author":"Schweitzer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.107833_bib20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3233\/JPD-212610","article-title":"The placebo response in double-blind randomised trials evaluating regenerative therapies for Parkinson's disease: a systematic review and meta-analysis","volume":"12","author":"Polgar","year":"2022","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107833_bib21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archneurol.2009.295","article-title":"The clinically important difference on the unified Parkinson's disease rating scale","volume":"67","author":"Shulman","year":"2010","journal-title":"Arch. Neurol."},{"issue":"s1","key":"10.1016\/j.parkreldis.2025.107833_bib22","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.3233\/JPD-223241","article-title":"Central and peripheral inflammation: connecting the immune responses of Parkinson's disease","volume":"12","author":"Williams","year":"2022","journal-title":"J. Parkinsons Dis."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025005747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025005747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T01:48:37Z","timestamp":1748742517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802025005747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":22,"alternative-id":["S1353802025005747"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107833","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogenic transplantation therapy of iPS cell-derived dopamine progenitors for Parkinson's disease \u2013Current status of the Kyoto Trial and future perspectives\u2013","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107833"}}